Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Non Operating Income (2022 - 2025)

Historic Non Operating Income for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$701000.0.

  • Atara Biotherapeutics' Non Operating Income fell 22630.63% to -$701000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.8 million, marking a year-over-year decrease of 10624.08%. This contributed to the annual value of -$2.0 million for FY2024, which is 70365.85% down from last year.
  • Per Atara Biotherapeutics' latest filing, its Non Operating Income stood at -$701000.0 for Q3 2025, which was down 22630.63% from -$807000.0 recorded in Q2 2025.
  • Over the past 5 years, Atara Biotherapeutics' Non Operating Income peaked at $50.6 million during Q2 2022, and registered a low of -$818000.0 during Q2 2024.
  • Moreover, its 4-year median value for Non Operating Income was -$204000.0 (2023), whereas its average is $3.2 million.
  • The largest annual percentage gain for Atara Biotherapeutics' Non Operating Income in the last 5 years was 37205.88% (2024), contrasted with its biggest fall of 36644.95% (2024).
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Non Operating Income stood at $969000.0 in 2022, then tumbled by 163.78% to -$618000.0 in 2023, then grew by 17.64% to -$509000.0 in 2024, then tumbled by 37.72% to -$701000.0 in 2025.
  • Its Non Operating Income was -$701000.0 in Q3 2025, compared to -$807000.0 in Q2 2025 and -$792000.0 in Q1 2025.